Analysis of binding affinities for celecoxib analogues with COX-1 and COX-2 from combined docking and Monte Carlo simulations and insight into the COX-2/COX-1 selectivity

被引:130
|
作者
Price, MLP [1 ]
Jorgensen, WL [1 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
关键词
D O I
10.1021/ja001018c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The origins of binding affinity and COX-2/COX-1 selectivity for analogues of celecoxib have been explored using an approach that combines docking with Monte Carlo (MC) simulations. These inhibitors are COX-2-selective nonsteroidal antiinflammatory drugs (NSAIDs) that are of current interest because the gastrointestinal irritation they cause is reduced compared to that caused by traditional NSAIDs. We report a novel docking method, based on a combined Tabu and Monte Carlo protocol, that determines starting conformations for MC simulations. Using the docking-predicted starting conformations, relative changes in binding free energies were computed for methyl, ethyl, hydroxymethyl, hydroxyl, thiomethyl, methoxy, trifluoromethyl, chloro, fluoro, and unsubstituted derivatives with the MC free energy perturbation (FEP) method. The computed free energies are in good accord with IC50 values, and the structural information from the simulations can be used to explain the experimentally observed binding trends. In addition, the docking and FEP results have provided clarification of the binding conformation of the phenylsulfonamide moiety and the origin of COX-2/COX-1 selectivity. Namely, the COX-2 Val --> COX-1 Ile subtitution is accompanied by an unfavorable conformational shift of the phenylsulfonamide ring.
引用
收藏
页码:9455 / 9466
页数:12
相关论文
共 50 条
  • [21] Distribution of COX-1 and COX-2 in normal and inflamed tissues
    Seibert, K
    Zhang, Y
    Leahy, K
    Hauser, S
    Masferrer, J
    Isakson, P
    EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY 2, PTS A AND B, 1997, 400 : 167 - 170
  • [22] The role of COX-1 and COX-2 isozymes in experimental cholera
    Gessell-Lee, DL
    Peterson, JW
    GASTROENTEROLOGY, 2001, 120 (05) : A323 - A323
  • [23] Does the COX-1/COX-2 concept still hold?
    Hawkey, C
    UPDATE GASTROENTEROLOGY 2004: NEW DEVELOPMENTS IN THE MANAGEMENT OF BENIGN GASTROINTESTINAL DISORDERS, 2004, : 87 - 89
  • [24] COX-2, but not COX-1, is involved in mechanotransduction in bone cells
    Bakker, AD
    Burger, EH
    Semeins, CM
    Klein-Nulend, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S215 - S215
  • [25] The pyrrole moiety as a template for COX-1/COX-2 inhibitors
    Dannhardt, G
    Kiefer, W
    Krämer, G
    Maehrlein, S
    Nowe, U
    Fiebich, B
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (05) : 499 - 510
  • [26] Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques
    McGeer, PL
    McGeer, EG
    Yasojima, K
    EXPERIMENTAL GERONTOLOGY, 2002, 37 (07) : 925 - 929
  • [27] Structure of COX-1 and COX-2 enzymes and their interaction with inhibitors
    Bakhle, YS
    DRUGS OF TODAY, 1999, 35 (4-5): : 237 - 250
  • [28] COX-1 and COX-2 tissue expression: Implications and predictions
    Crofford, LJ
    JOURNAL OF RHEUMATOLOGY, 1997, 24 : 15 - 19
  • [29] COX-1 and COX-2 in human periodontal disease states.
    Marshall, RI
    Gemmell, E
    Carter, C
    Bartold, PM
    Seymour, GJ
    Brooks, P
    JOURNAL OF DENTAL RESEARCH, 2001, 80 (04) : 978 - 978
  • [30] Comparison of celecoxib and rofecoxib on COX-1 and COX-2 activity in whole blood assays.
    Schwartz, J
    Porras, A
    Wong, P
    Van Hecken, A
    De Lepeleire, I
    Dallob, A
    Hunt, T
    Ebel, D
    Gumbs, C
    Gottesdiener, K
    Gertz, B
    De Schepper, P
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1059 - 1059